Mark Lewis: Oncology has a PR problem
Mark Lewis shared a post by Jeff Ryckman, on X/Twitter, adding:
History will judge us harshly for being blunt instruments but the arc is bending towards greater precision and less indiscriminate toxicity”
Quoting Jeff Ryckman‘s post:
Our accuracy is within 2-3mm. VMAT improves treatment times w/o compromising safety or efficacy. Yet, these advancements seem overshadowed by negative perceptions. Studies showing significant survival improvements don’t make headlines like they would if they were about a new drug
This lack of media attention could be due to the absence of substantial marketing budgets in radiotherapy, unlike the pharmaceutical industry. We don’t have the luxury to market our treatments aggressively.
We must advocate for radiation oncology and monitor media portrayal, as our influence is less than that of the pharmaceutical lobby, despite being a cost-effective cancer treatment. I’m skeptical of The New York Times‘s understanding of modern radiotherapy. We hope other news outlets like The Free Press
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023